<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Steg, Philippe Gabriel</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results of the PLATelet Inhibition and Patient Outcomes (PLATO) Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses a subset analysis of the larger PLATO trial where ticagrelor was superior to clopidogrel in terms of preventing cardiovascular death, myocardial infarction, or stroke in patients who presented with STEMI and for whom PCI was planned, without causing a significant increase in major bleeding.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>